Q1 2026 Phathom Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Phathom Pharmaceuticals Inc (PHAT) more than doubled its revenue from Q1 2025 to Q1 2026, indicating strong growth.
- The company is on track to potentially achieve $1 billion in annual revenue from gastroenterology prescriptions.
- Phathom Pharmaceuticals Inc (PHAT) expanded its sales team with nearly 50 new sales representatives, enhancing its market reach.
- Vequezna achieved approximately 45% new-to-brand prescription market share among top gastroenterology writers, showing strong adoption.
- The company maintained its revenue guidance for the year, reflecting confidence in its growth trajectory.
- Q1 2026 revenue was somewhat light compared to internal expectations due to market access seasonality and other factors.
- Cash operating expenses were $56.2 million for Q1, reflecting a significant cost burden.
- The company faces potential competition from a new PCAB entrant in the U.S. market, which could impact market dynamics.
- There is uncertainty about the impact of a second PCAB entrant on Phathom Pharmaceuticals Inc (PHAT)'s sales trajectory in 2027 and beyond.
- The company is still in early days of tracking metrics for patients cycling back to primary care, indicating a need for further data collection.
Hello, and welcome to the Fathom Pharmaceuticals First Quarter 2026 Earnings Result Call. (Operator Instructions) I would like to turn the call over to Eric Chiarelli, Fathom's Head of Investor Relations. Please go ahead.
Thank you, operator. Hello, everyone, and thank you for joining us this morning to discuss Fathom's first-quarter 2026 results.
This morning's presentation will include remarks from Steve Basta, our President and CEO, and Sanjeev Narula, our Chief Financial and Business Officer.
A couple of notes before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the News Releases section of our corporate website. Further, the recording of today's webcast and the slides we'll be reviewing can also be found on our corporate website under the Events and Presentations section.
Before we begin, let me remind you that we will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
